Dissecting out the unexpected effects of SGLT2 inhibitors on human ageing
Clicks: 1
ID: 313500
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #320 of 362 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 362 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal tubules, thereby promoting urinary glucose excretion. Although originally developed as antidiabetic agents, large-scale clinical trials have demonstrated that SGLT2 inhibitors not only lower blood glucose levels but also significantly reduce cardiovascular and renal events in patients with diabetes. Subsequent studies further established that these agents confer cardio-renal protection in individuals with heart failure or chronic kidney disease, irrespective of diabetes status. Beyond these established clinical benefits, accumulating evidence suggests that SGLT2 inhibitors may exert anti-aging effects. Mechanistically, they induce metabolic adaptations that resemble caloric restriction and ketogenic states, attenuate systemic inflammation, improve mitochondrial function, and enhance cellular resilience against the burden of senescence. Supporting this concept, multiple preclinical studies have shown that SGLT2 inhibitors extend lifespan and ameliorate age-related functional decline in animal models. Notably, recent findings indicate that SGLT2 inhibitors can reduce senescent cell burden and modulate the senescence-associated secretory phenotype (SASP), raising the possibility that they possess senotherapeutic-or even senolytic-properties targeting a fundamental driver of aging. Collectively, these data suggest that SGLT2 inhibitors may influence core aging pathways beyond their glucose-lowering and cardio-renal protective effects. In this review, we summarize current insights into the molecular and physiological mechanisms by which SGLT2 inhibitors may modulate aging biology and discuss their emerging potential as therapeutic agents capable of extending health span and preventing age-related diseases.
| Reference Key |
openalex_W7161181390
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Goro Katsuumi, Tohru Minamino |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag207
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.